The objective of this study was to analyze the molecular profile of a cohort of patients suffering from recurrent GBM, IDH-wildtype, treated with regorafenib, with the aim to identify factors that may predict response to this multikinase inhibitor. The gene discussed is IDH1; the disease is glioblastoma.